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Simple Summary: Up to 90% of bladder cancers originate from the cells that line the interior of the
bladder and are called urothelial carcinomas (UC). Faster growth of UC leads to a higher demand for
nutrients and energy than non-malignant cells. UC compensates for this high demand for energy and
building blocks by upregulation of different metabolic and bioenergetic pathways, in a process which
is known as metabolic reprogramming (MR). However, this MR creates an environment within the
tumor that alters immune cells, which in turn reduces the effectiveness of anticancer treatments such
as immunotherapy. Here, we review UC MR and its impact on immune cells in UC in order to explore
research opportunities that may improve immunotherapy. We discuss the current understanding of
UC MR in animal models and summarize clinical trials that are investigating metabolism as a target
to enhance immunotherapy in UC patients.
Abstract: Metabolic reprogramming (MR) is an upregulation of biosynthetic and bioenergetic path-
ways to satisfy increased energy and metabolic building block demands of tumors. This includes
glycolytic activity, which deprives the tumor microenvironment (TME) of nutrients while increasing
extracellular lactic acid. This inhibits cytotoxic immune activity either via direct metabolic compe-
tition between cancer cells and cytotoxic host cells or by the production of immune-suppressive
metabolites such as lactate or kynurenine. Since immunotherapy is a major treatment option in pa-
tients with metastatic urothelial carcinoma (UC), MR may have profound implications for the success
of such therapy. Here, we review how MR impacts host immune response to UC and the impact on
immunotherapy response (including checkpoint inhibitors, adaptive T cell therapy, T cell activation,
antigen presentation, and changes in the tumor microenvironment). Articles were identified by
literature searches on the keywords or references to “UC” and “MR”. We found several promising
therapeutic approaches emerging from preclinical models that can circumvent suppressive MR
effects on the immune system. A select summary of active clinical trials is provided with examples
of possible options to enhance the effectiveness of immunotherapy. In conclusion, the literature
suggests manipulating the MR is feasible and may improve immunotherapy effectiveness in UC.
Keywords: bladder; urothelial cancer; metabolic reprogramming; immunotherapy
1. Introduction
Worldwide, there were approximately 550,000 new cases and 200,000 deaths from
bladder cancer (BC) in 2018 [1]. Up to 90% of BC cases originate from the luminal urothe-
lial lining of the bladder and produce urothelial carcinomas (UC). Non-muscle invasive
UC (NMIUC) accounts for 75% of BC patients and is commonly treated by transurethral
tumor resection (TUR) with and without adjuvant intravesical instillations [2]. In contrast,
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muscle-invasive UC (MIUC) is treated with either cisplatin-based neoadjuvant chemother-
apy (NAC) followed by surgical removal of the bladder (cystectomy) or external beam
radiotherapy with or without chemotherapy. Despite extensive treatment, half of MIUC
patients will progress to metastatic urothelial carcinoma (mUC) [3]. First-line treatment
option in mUC is gemcitabine + cisplatin (“gem/cis”) [3,4]. However, 30% of mUC pa-
tients are cisplatin-ineligible due to poor performance status and other comorbidities [5,6].
Cisplatin-ineligible patients, mostly due to renal compromise, are treated with gemcitabine
+ carboplatin (“gem/carbo”), which is less effective than cisplatin combinations [7]. Re-
gardless of the platinum-based chemotherapy used, most mUC patients will ultimately
progress [8]. In recent years, immune checkpoint therapy (ICT) has emerged as a new
option for platinum-relapsed or cisplatin-ineligible patients [3]. ICT targets cytotoxic T
lymphocyte antigen 4 (CTLA4) and programmed death (ligand) 1 (PD-1/PDL1), used
by tumor cells to inhibit anticancer immune responses [9]. ICT has shown superior effi-
cacy over 2nd line chemotherapy in platinum-relapsed mUC patients [10–12]. Currently,
several PD-1/PD-L1 inhibitors have been FDA, and EMA approved for the treatment of
mUC in the first line (no prior platinum-based chemotherapy) and/or second-line (af-
ter the failure of platinum-based chemotherapy) [10–14]. Approved agents used PD-L1
inhibitors: atezolizumab, durvalumab, and avelumab, and PD-1 inhibitors: nivolumab
and pembrolizumab [10–12]. Treatment of platinum-relapsed mUC patients with pem-
brolizumab, nivolumab, or atezolizumab was associated with an ORR of ~20% [10–12].
Robust biomarkers that can predict clinical response to ICT are lacking due to the complex-
ity of tumor-immune interactions that contribute to ICT resistance [15]. However, it was
found recently that a mechanism associated with resistance to ICT is metabolic competition
between immune cells and cancer cells in the tumor microenvironment (TME) [16,17].
Here, we review how the metabolic profile of normal urothelial cells is reprogrammed with
malignant transformation and progression and how this contributes to immune evasion
and resistance to ICT. We then examine how these findings can be exploited therapeutically
to enhance ICT in UC patients.
2. Glucose Metabolism in Urothelial Carcinoma
Glucose metabolism produces energy in the form of ATP and precursor metabolites
used for biosynthesis. Glucose metabolism starts with a process called glycolysis that
consists of stepwise conversions of glucose that ultimately generates pyruvate. The rate of
glycolysis is regulated by hexokinase (HK), glucose-6-phosphate dehydrogenase (G6PD),
phosphofructokinase (PFK), and pyruvate kinase (PK) (Figure 1). Pyruvate participates in
the tricarboxylic acid (TCA) cycle, also known as the citric acid cycle (CAC), or Krebs cycle,
where it is ultimately oxidized into water and carbon dioxide. This oxygen-dependent
process is called oxidative phosphorylation and ultimately produces 32–38 ATP molecules
from one glucose molecule. In the absence of oxygen, pyruvate is transformed into lactate,
producing 2 ATP molecules for every glucose molecule. In cancer cells, metabolic repro-
gramming (MR) refers to an upregulation of biosynthetic and bioenergetic pathways to
produce the necessary materials and energy required for tumor growth. MR includes a shift
in glucose metabolism from oxidation to glycolysis despite the presence of oxygen. This is
commonly known as aerobic glycolysis [18] or the Warburg effect and favors the usage of
glucose’s carbon atoms for gaining biomass (i.e., metabolic building blocks) over energy
(i.e., ATP) production. Because cancer cells also need more energy, yet this arrangement is
energy inefficient, there is a compensatory increase in glucose consumption [19]. Glucose
uptake is seen in UC by way of positron emission tomography/computed tomography
(PET/CT), which uses radioactively labeled glucose-analog fluorodeoxyglucose (18F-FDG)
to visualize primary tumors and metastases [3]. Human UC cell lines also show increased
uptake of glucose compared to untransformed urothelial cells and produce increased levels
of pyruvate and lactate [20]. Evaluation of the patient’s UC tumor samples indicates glu-
cose quantity was significantly lower compared to normal urothelium [21]. Furthermore,
late TCA cycle intermediates were also increased in UC, suggesting flux into the TCA
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cycle to replenish intermediates extracted from the cycle for biosynthesis—a process called
anaplerosis [21]. A significant increase of ribose, the end-product of the pentose phosphate
pathway (PPP), was also observed in UC, suggesting upregulation of the PPP [21]. The
PPP occurs in the cytosol and consists of an oxidative phase that produces NADPH, which
is required for reductive processes such as fatty acid synthesis and scavenging of reactive
oxygen species, and a non-oxidative phase that produces pentoses like ribose, which are im-
portant precursors for nucleotide synthesis. Therefore, the PPP helps metabolically active
or proliferating cells to meet their anabolic demands and combat oxidative stress [22,23].
Thus, UC alters its metabolism and consumes glucose to produce energy via glycolysis,
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Figure 1. Metabolic reprogramming of glucose metabolism in UC. Oxygen-dependent hypoxia-inducible factor 1 alpha (HIF-
1α) and oxygen-independent PI3K/AKT/mTOR and PPARy signaling (yellow boxes) drive metabolic reprogramming in UC
by controlling the activity of rate-limiting enzymes (blue boxes) or transp rters. Numbers (orange boxes) indicate which gene
drives activation of particular rate-limiting enzymes or transporters. Glucose is imported into the cell by glucose transporters
(GLUT) 1 and 3. Glycolysis starts with phosphorylatio f glucose by h xokinase (HK) to glucose-6-phosphate, preventing
glucose from diffusing outside the cell. Glucose-6-phosphate can be dehydrogenated by glucose-6-phosphate dehydrogenase
(G6PD) to enter the pentose phosphate cycle (PPP) to produce pentoses like ribose-5-phosphate required for the synthesis of
nucleotides and NADPH, which is n cessary for reductive processes such as lipid biosynthesis. If glucose-6-phosphate is
not oxidized by G6PD, glucose-6-phosphate is isomerized by phosphoglucose isomerase/phosphoglucoisomerase (PGI)
to fructose-6-phosphate. Next, phosphofructokinase (PFK) catalyzes the phosphorylation of fructose-6-phosphate to
fructose-1,6-biphosphate, which irreversibly channels the glucose-derived metabolite into the glycolytic pathway towards
phosphoenolpyruvate. At the end of the glycolytic pathway, pyruvate kinase (PK) catalyzes the dephosphorylation of
phosphoenolpyruvate (PEP) to produce one pyruvate and one ATP molecule. Pyruvate is then metabolized into lactate-
by-lactate dehydrogenase (LDH). Lactate is transported outside the cell by monocarboxylate transporters (MCT) 1 and 2,
which leads to an increased concentration of extracellular lactate and an acidified tumor micro-environment. Pyruvate can
also be metabolized into acetyl coenzyme A (acetyl-CoA), which participates in the tricarboxylic acid (TCA) cycle inside
mitochondria to give rise to ATP and intermediary metabolites that are required for lipid and amino acid biogenesis.
Cancers 2021, 13, 288 4 of 14
3. Regulation of Glucose Transport and Metabolism in UC
Cellular glucose utilization is regulated by oxygen-dependent and oxygen-independent
mechanisms that rely on several common glucose transporters and glycolytic enzymes
(Figure 1). Oxygen-dependent mechanisms are mediated by transcription factor hypoxia-
inducible factor 1-alpha (HIF-1α) [24,25]. Low oxygen tension stabilizes HIF-1α protein
expression, which translocates to the nucleus and binds to target genes, thereby upregulat-
ing gene expression [26,27]. HIF-1α indirectly stimulates glycolysis through inhibition of
mitochondrial biogenesis and oxygen consumption through induction of pyruvate dehy-
drogenase kinase 1 (PDK1), which subsequently inhibits pyruvate dehydrogenase from
catalyzing oxidative decarboxylation of pyruvate [28,29]. The steroid receptor coactivator-3
(SRC-3) is a HIF-1α co-activator required for the expression of several HIF1-1α target genes
in T24 UC cells under hypoxia [30]. Another HIF-1α co-activator is histone demethylase
JMJD1A, whose H3K9 demethylase activity is required at promotor sites to induce expres-
sion of several key glycolytic enzymes [31]. Interestingly, JMJD1A was found upregulated
in 46 UC patient samples, compared to 14 normal bladder samples [31]. In summary, UC
has higher levels of HIF-1α co-activators, which leads to more glycolysis and reduced
oxidative phosphorylation.
Oxygen-independent mechanisms of glucose utilization in UC are primarily mediated
through activation of the PI3K/AKT/mTOR pathway [32,33]. The PI3K/AKT/mTOR
pathway consists of activators: phosphatidylinositol 3-kinase (PI3K), protein kinase B
(AKT), mammalian target of rapamycin (mTOR), and PI3K-inhibitor: phosphatase and
tensin homolog (PTEN). Mutations in genes of the PI3K/AKT/mTOR pathway are present
in 42/131 (38%) patients with MIUC [34]. Besides activating mutations, other factors may
also promote PI3K/AKT/MTOR signaling in UC. For example, microRNA 21 (Mir-21)
activates PI3K/AKT/mTOR signaling through inhibition of PTEN expression in UC cell
line T24, thereby stimulating glycolysis [32,35]. Furthermore, long non-coding RNA UCA1
is associated with mTOR-mediated glucose consumption and lactate production in 5637
human bladder carcinoma cells, although no direct interaction between mTOR and UCA1
was demonstrated [33].
Peroxisome proliferator-activated receptor gamma (PPARy) has been implicated as
a driver of oxygen-independent activation of glycolysis in breast cancer and hepatocel-
lular carcinoma murine models through transcriptional activation of key glycolytic en-
zymes [36,37]. In UC, the increased transcriptional activity of PPARy was associated with
increased mRNA expression of glycolytic enzymes and decreased recurrence-free sur-
vival in a subset of 140 non-invasive (pTa) bladder tumors [38]. Interestingly, PPARy, like
PI3K/AKT/mTOR signaling, is commonly associated with the luminal subtype of MIUC,
which has a relatively good prognosis [39–41].
Increased glycolytic flux is associated with increased glucose uptake by glucose trans-
porters. Glucose transporter 1 (GLUT1) is the primary glucose transporter overexpressed
in cancer [42]. Expression of GLUT3 has also been demonstrated in T24 UC cells [43,44].
GLUT1 protein overexpression was associated with worse overall and disease-free survival
in a pooled analysis of 4079 patients with various tumor types, not including UC [45].
GLUT1 expression evaluated by immunohistochemistry (IHC) in 105 BC samples was
associated with an increased grade in both NMIUC and MIUC [46]. Furthermore, GLUT1
overexpression by IHC was an independent predictor of survival following radiotherapy
(N = 64) or radical cystectomy (N = 279) for MIUC [47,48]. GLUT1 expression is gener-
ally induced by HIF-1α, indicating oxygen-dependent GLUT1 expression [49]. Likewise,
GLUT1 and GLUT3 expression seem also to be controlled by microRNAs that function
through altering PI3K/AKT/mTOR signaling in vitro [32]. Mir-218 was found to repress
GLUT1 expression and, as a consequence, glucose uptake in T24 cells, while Mir-195-5p
did the same for GLUT3 [43,44]. GLUT1 knockdown elevated intracellular reactive oxygen
species (ROS) and increased cisplatin sensitivity in T24 cells [43].
Once glucose is imported into the cell, hexokinase (HK) (Figure 1) is the first rate-
limiting enzyme controlling glycolytic flux. HK has four isoforms characterized by different
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functions and cellular locations. Isoform HK2 is linked to an anabolic function through
PPP and has been implicated in UC MR [33,50,51]. T24 cells overexpress HK2 in response
to PI3K/AKT/mTOR signaling [32]. Pharmacological inhibition of HK2 in UC cell line
UM-UC-3 lowered glucose consumption and lactate production, accentuating a potential
role in UC glucose metabolism [52].
UC cells also have upregulated phosphofructokinase (PFK) (Figure 1), which drives
increased glycolytic flux. Somatic genetic aberrations that upregulate or amplify PFK
family genes are present in ~40% of MIUC patients [50]. In vitro studies with UC cell
lines, RT4, and TCCSUP suggested that PFK is primarily important during early phases of
cancer progression, as PFK expression was higher in RT4 (representing early-stage, well-
differentiated NMIUC) compared to TCCSUP (representing more progressed, anaplastic
MIUC) [51]. Moreover, a lower PFK activity was associated with increased pyruvate
consumption, implying that more progressed tumors start to directly metabolize pyruvate
instead of glucose [51]. PFK is indirectly activated by one of four 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase (PFKFB) enzymes. PFKFB3 is expressed in T24, and
knockdown led to decreased lactate production [53]. Another PFKFB family member,
PFKFB4, was found expressed in 135 UC radical cystectomy samples [54]. High PFKFB4
expression assessed by IHC was associated with increased tumor stage and grade, and
subsequent in vitro experiments demonstrated that PFKFB4 expression was induced during
hypoxia in an HIF-1α-dependent manner [54].
The last step of glycolysis converts phosphoenolpyruvate (PEP) and ADP to pyruvate
and ATP, and this step is catalyzed by pyruvate kinase (PK) isozymes M1/M2 (PKM1/M2)
(Figure 1). UC cell lines have been shown to reexpress PKM2 [55].
In cancer cells, pyruvate is metabolized to lactate-by-lactate dehydrogenase (LDH),
which reduces NADH to NAD+ in the same process. Lactate production replenishes
cytosolic NAD+, allowing a continuous glycolytic flux [56,57]. Lactate produced by LDH
is exported across the cell membrane by monocarboxylate transporters (MCT) in order to
maintain an alkaline intracellular pH, favoring metabolism [58,59]. Tumor cells depend
on MCT4 and, to a lesser extent, on MCT1 for lactate export, and MCT4 is expressed in
a HIF-1α dependent manner [59,60]. MCT4 was overexpressed in approximately 50% of
360 UC patients, as assessed by IHC [61]. Moreover, MCT4 protein overexpression was an
independent prognostic factor, predicting poor recurrence-free survival in NMIUC and
MIUC patients treated with transurethral resection or radical cystectomy [61]. Likewise,
MCT4 mRNA and protein expression predicted poor overall survival in MIUC patients
treated with radical cystectomy [62]. Short interference RNA (siRNA) mediated silencing
of MCT4 in UC cell lines, reduced proliferation rates, and increased ROS in a glucose-
dependent manner [62]. Moreover, stable shRNA knockdown of MCT4 impaired tumor
growth in an orthotopic UC xenograft model [62].
In conclusion, evidence shows that UC uses HIF-1α to increase glycolytic flux and to
neutralize ROS via the upregulated activity of glucose importers (GLUT1, GLUT3), gly-
colytic enzymes (PFK), and lactate transporters (MCT4). Meanwhile, PI3K/AKT/mTOR
signaling contributes to upregulating glycolytic enzymes (HK). Inhibiting glycolysis and
lactate production may target UC either directly by impairing metabolic activity. How-
ever, most mechanistic evidence was gathered in small studies investigating parts of UC
metabolism in a few human UC cell lines. More comprehensive preclinical investigation of
UC metabolism in different stages of the disease is needed to increase the validity of these
findings before translation into clinical trials.
4. Impact of UC Metabolism on Cells of the Tumor Microenvironment
and Immunotherapy
The tumor microenvironment (TME) is a critical determinant of tumor behavior and
treatment response [63]. The TME is metabolically influenced by tumor cells in general,
and also, UC influences the TME through MR [18,64,65]. Molecular aberrations driving
MR can differ between tumor types (i.e., PI3K-activating mutations and increased PPARy-
activity are characteristic drivers of UC); the outcome of MR on the TME seems to be
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more general and is summarized in Figure 2. Increased metabolic activity of tumor cells
causes glucose and amino acid deprivation in the TME. Low glucose availability leads to
metabolic competition between effector T cells and tumor cells [18,66,67], altering tumor-
infiltrating lymphocytes effector function and immune response to the tumor [66,68,69].
This is in part due to T cell metabolism being glycolysis dependent and driven by HIF-
1α, PI3K/AKT/mTOR, and PPARy signaling [17,64,65,70,71]. However, a recent study
found that T cell viability, activation, and effector functions were preserved in a low
glucose environment in vitro [66]. This suggests that restricting glucose consumption does
not necessarily render T cells ineffective, possibly because T cells resort to alternative
metabolic substrates. For instance, CD8+ T cells have been shown to metabolize inosine
in order to produce glycolytic intermediates [67]. In line with previous observations, an
artificial increase of the late glycolytic intermediate, PEP, rescued loss of T cell effector
functions caused by glucose-deprivation [68]. Another study found evidence supporting
the hypothesis that CD8+ T cells resort to fatty acid and self-produced ketone bodies as
alternative metabolic substrates when confronted with hypoxia and glucose restrictions [69].
Interestingly, fatty acid catabolism could be further stimulated in CD8+ tumor-infiltrating
lymphocytes using the selective PPARα agonist, fenofibrate [69]. Additionally, fenofibrate
pretreatment of CD8+ T cells was able to slow down tumor growth in vivo, using an
adoptive T cell transfer (ACT) [71]. As mentioned earlier, luminal subtype UC is driven by
PPARy activation [39,41]. Therefore, a therapeutic agent that combines PPARy-antagonism
with PPARα-agonism may be a suitable strategy to boost immunotherapy in bladder
cancer. This evidence leads to the conclusion that glucose deprivation inhibits glycolytic
activity in CD8+ T cells, but there may be ways to prevent negative consequences on T cell
effector function.
Indoleamine-2,3-dioxygenase (IDO) is a rate-limiting enzyme for tryptophan
metabolism, and its overexpression in cancer cells leads to tryptophan depletion in the
TME, in which immune-suppressive kynurenine accumulates [72,73]. Subsequent trypto-
phan shortages induce a proliferation arrest in CD8+ T cells [74]. Several clinical trials have
been investigating whether restoring TME tryptophan levels and preventing kynurenine
accumulation through IDO-inhibition can boost ICT in UC. A phase I/IIa trial investigated
IDO-inhibitor BMS-986205 in combination with nivolumab in patients with advanced UC
(NCT02658890). An overall response rate (ORR) of 37% was observed among 27 ICT-
naive advanced UC patients, supporting further evaluation of IDO inhibition to boost
immunotherapy [75]. However, it is difficult to interpret the high ORR of 37% without
a comparison arm receiving only nivolumab treatment or information on PD-L1 expres-
sion. Another phase I study is currently investigating the safety profile of IDO-inhibitor
KHK2455 in combination with avelumab in platinum-relapsed metastatic UC patients
(NCT03915405). The PECULIAR phase II trial is investigating neoadjuvant pembrolizumab
combined with IDO-inhibitor epacadostat in MIUC patients prior to radical cystectomy
(NCT03832673). Epacadostat will also be evaluated as a neoadjuvant treatment option in
a phase II umbrella study that allocates treatment according to FGFR3 mutation status
(NCT04586244). Treatment with either epacadostat alone, or in combination with anti-PD-1
monoclonal antibody retifanlimab will be available for MIUC patients without FGFR3 muta-
tions or fusions, who do not qualify for FGFR-directed therapy (NCT04586244). Two phase
III studies are currently investigating clinical efficacy of pembrolizumab + epacadostat in
platinum-relapsed mUC patients (NCT03374488, NCT03361865). Moreover, safety and
preliminary efficacy of IDO1 inhibitor epacadostat in combination with arginase inhibitor
INCB001158 and pembrolizumab is under investigation in patients with solid tumors,
including mUC (NCT03361228).
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Figure 2. How urothelial cancer metabolism impacts immune cells in tumor microenvironment (TME). Urothelial cancer
creates an acidic TME deprived of glucose, tryptophan, and arginine, whereas concentrations of immune-suppressive
molecules, such as lactate and kynurenine, are increased. Excessive lactate in the TME inhibits the tumor immune response
by (1) polarization of macrophages to a suppressive M2 phenotype, (2) inhibition of monocyte migration and differentiation
into dendritic cells (DC), thereby inhibiting antigen presentation and subsequent T cell activation, (3) by stimulating
immune-suppressive myeloid-derived progenitor cells (MDSCs) to breakdown immune-stimulatory arginine, or (4) through
direct inhibiti n of CD8+ T cell function by lactate. The T-cell-mediated mmune response is also directly inhibited by
tumor-produced kynurenin and indirectly through tumor-induced tryptophan a d glucose shortage.
It has been demonstrated that oxygen-tension in the TME could be raised to benefit
immun the py by inhibiting oxidative phosphorylation in vivo [76]. Metformin is a drug
widely used for diabe c patients that uncouples xidativ phosphorylation. Metformin
monoth rapy was found to decrease tumor growth of 5637 human bladder carcinoma cells
in nude mice [77] and boost the efficacy f anti-PD-1 therapy (J43) in a murine melanoma
odel [76]. A phase 2 clinical trial is investigating the preliminary efficacy of metformin in
combination with nivolumab for treating metastatic lung cancer patients (NCT03048500).
A hypoxic TME drives oxygen-dependent upregulation of UC’s glucose consumption
and lactate production. Lactate is exported extracellularly, where concentrations can rise
up to 40 mM compared to the physiological concentration of 1–3 mM [78–81]. The high
lactic acid in the TME promotes angiogenesis, metastasis, and immune escape [82].
Tumor-immune responses are initiated by tumor-associated dendritic cells. Tumor-
associated dendritic cells develop from monocytes and play a central role in tumor im-
munity by capturing neoantigens and presenting neoantigens to T cells, which initiates
a T-cell-mediated immune response directed at neoantigen expressing tumor cells [83].
Lactate concentrations of 20nM inhibited both monocyte migration and the release of
immune-stimulatory cytokines like interleukin-6 and tumor necrosis factor (TNF) [84].
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In addition, lactic acid changes the differentiation of monocytes into dendritic cells and
inhibited antigen presentation of dendritic cells [85]. Tumoral lactate production was also
found to increase the presence of myeloid-derived suppressor cells (MDSC), which have
inhibitory effects on cytotoxic T cells [86]. Recently, it was discovered that MDSC suppress
T cells via the transfer of the glycolytic byproduct methylglyoxal, which had an inhibitory
effect by depleting L-arginine in CD8+ T cells, thereby paralyzing antitumor immunity [87].
Two clinical trials are currently investigating the possibility of restoring arginine levels
to enhance immunotherapy. A phase 1 trial enrolling up to 260 patients with metastatic
solid tumors, including UC patients, is investigating arginase inhibitor INCB001158 in
combination with pembrolizumab (NCT02903914). Arginase is produced by MDSC and
breaks down proinflammatory arginine thus blocking arginase activity and may partially
restore antitumor immune responses. Likewise, the safety of a cell-permeable l-arginine
analog, NG-monomethyl-L-arginine (L-NMMA), is being investigated in combination with
pembrolizumab in a phase 1b trial also enrolling UC patients (NCT03236935).
Tumor-associated macrophages (TAMs) are generally considered unfavorable, driv-
ing tumor progression and metastasis [88]. However, TAMs have a dual role, as pro-
inflammatory M1 macrophages with anti-tumor activity and M2 macrophages promoting
tumor growth and immune escape [89]. Lactate produced by tumor cells has been shown
to polarize M1 macrophages to an M2 phenotype mediated through increased expression
of HIF-1α in TAMs [90,91]. This was first demonstrated in vitro when TAMs from patients
showed increased HIF-1α expression and M2 polarization when treated with either lactate
or conditioned medium derived from Lewis lung carcinoma (LLC) and melanoma cell lines
in vitro [90]. A similar mechanism has been shown for bladder cancer, as either co-culture
of murine RAW 264.7 macrophages with T24 UC cells or lactate treatment inhibited M1
polarization, while M2 polarization was induced [91]. It remains to be determined how
lactate exactly increases M2 polarization in TAMs, but the mechanism seems to depend
on HIF-1α expression and the intracellular lactate levels of macrophages, as the effects of
lactate treatment on TAM polarization could be averted through the blocking of lactate
transporters with MCT-inhibitor quercetin or HIF-1α knockdown [90,91]. Thus, extra-
cellular lactate can be immune suppressive by decreasing the presence and activity of
tumor-associated dendritic cells while activating MDSC-mediated immune suppression
and driving M2 macrophage polarization.
Lactate production can also decrease T-cell function [92–94]. The high presence of
lactic acid in the TME reduces the gradient-dependent export of lactate through MCT1,
thereby disturbing cytotoxic T cell metabolism as intracellular lactate accumulates and
intracellular pH drops [93,94]. Interestingly, extracellular sodium lactate (associated with
neutral/increased pH) was found to inhibit CD4+ T helper cell motility and stimulate
the production of proinflammatory interleukin-17, whereas lactic acid (associated with
decreased pH) caused the loss of cytolytic activity of CD8+ T cells [92]. Whereas, an
extracellular lactate concentration of 20 mM, measured by the routinely used AVDIA
1650 chemical analyzer, was enough to decrease proliferation and cytokine production of
cytotoxic T cells by 95%, while cytotoxic activity towards melanoma cells was decreased by
50% [94]. Moreover, intratumoral pH measured by microelectrode could be increased from
pH 6.8 to pH 7.0 in melanoma xenografts fed with 200 mM bicarbonate drinking water [95].
Neutralizing tumor acidity with oral bicarbonate treatment synergized with either adoptive
T cell transfer, anti-CTLA4 or anti-PD-1 treatment in two melanoma xenograft models [95].
Safety of bicarbonate supplementation in humans has been assessed in 15 healthy volun-
teers, and dosage of up to 0.17 g/kg/day for 90 days was well tolerated (0.5 g/kg/day
was the predicted equivalent of 200 mM bicarbonate drinking water fed to the xenografts),
suggesting that moderate, oral bicarbonate supplementation might be feasible for cancer
patients [96]. These results imply that the earlier described balance between immune-
stimulatory sodium lactate and immune-suppressing lactic acid could be used as a switch
to turn on the tumor immune response, although no clinical trials have been reported to
investigate bicarbonate treatment with immunotherapy.
Cancers 2021, 13, 288 9 of 14
LDH knockdown in melanoma xenograft model diminished intratumoral lactate con-
centrations while increasing concurrent CD8+ T cell tumor infiltration and reducing tumor
growth in a melanoma xenograft model [93]. Most recently, shRNA knockdown of LDH
synergized with anti-PD-1 treatment while confirming that limiting lactate production
led to increased infiltration of T cells and NK cells [97]. Nonetheless, treatment with
LDH-inhibitor GSK2837808A was additive but not synergistic with adoptive T cell transfer
treatment in another melanoma xenograft model [98]. That pharmacological inhibition
of LDH is additive to immunotherapy, but that genetic inhibition is synergistic may be
explained by metabolic similarities between immune and cancer cells [17]. In contrast to the
described lack of synergism when lactate production is targeted using a pharmacological
approach, there has been reported synergism with diclofenac-mediated inhibition of lactate
transporters MCT1 and MCT4, present both on tumor cells and T cells, in combination
with anti-PD1 and anti-CTLA4 therapy in melanoma xenografts [68]. This indicates that
blocking lactate transport may be a window of opportunity to boost immunotherapy. Clin-
ical evidence for the hypothesis that a high glycolytic flux and increased lactate production
hampers immunotherapy was obtained in 47 melanoma patients who received anti-PD-1
therapy [68]. Patients with a predicted high glycolytic index, based on mRNA expression
of glycolytic enzymes, had a worse progression-free survival than patients with tumors
that had a low glycolytic activity [68]. At present, there are no reported clinical trials inves-
tigating the effects of targeted glucose metabolism or lactate production in combination
with ICT (Table 1).
Table 1. Clinical trials investigating metabolic reprogramming for immunotherapy.
Drug Target Combination Therapy Setting Identifier
INCB001158 Arginase Pembrolizumab Solid tumors, includingUC NCT02903914
L-NMMA Nitric oxide synthase Pembrolizumab Solid tumors, includingUC NCT03236935
BMS-986205 IDO Nivolumab mUC NCT02658890
KHK2455 IDO Avelumab Platinum-relapsedmUC NCT03915405
Epacadostat IDO Pembrolizumab Platinum-relapsedmUC
NCT03374488,
NCT03361865
Epacadostat IDO Pembrolizumab Neoadjuvant MIUC NCT03832673,







Metformin Hypoxia, oxidativephosphorylation Nivolumab NSCLC NCT03048500
IDO = indoleamine 2,3-dioxygenase, UC = urothelial cancer, mUC = metastatic urothelial cancer, MIUC = muscle-invasive bladder cancer,
NSCLC = non-small cell lung cancer.
5. Concluding Remarks and Future Perspectives
The TME is a complex environment that includes cells with both proinflamma-
tory as well as immune suppressive responses. Metabolic reprogramming of urothelial
cells that undergo transformation into UC is exemplified by hypoxia, PPARy and/or
PI3K/mTOR/AKT signaling-mediated upregulation of PPP, increased anaplerosis through
the TCA, and most importantly, increased glycolysis and lactate production.
These changes deprive the TME of nutrients, while extracellular, immune-suppressive
molecules like lactic acid or kynurenine increase, thereby contributing to immune evasion.
Combining ICT with approaches that target UC metabolism may benefit the metabolic
demands of immune cells with antitumor activity such as M1 macrophages or CD8+ T cells.
Clinical trials are currently combining ICT with drugs targeting tumor-induced arginine-
depletion or immune-suppressive metabolites in UC patients. Arginase depletion can
be countered through arginase-inhibition, which is being evaluated in combination with
pembrolizumab (NCT02903914). Additionally, IDO-inhibition could overcome both trypto-
Cancers 2021, 13, 288 10 of 14
phan depletion and accumulation of immune-suppressive kynurenine. IDO-inhibition is
under investigation in combination with pembrolizumab (NCT03374488, NCT03361865),
nivolumab (NCT02658890), avelumab (NCT03915405), and retifanlimab (NCT04586244).
Strategies that inhibit UC glycolysis and lactic acid production seem promising methods to
boost the effectiveness of ICT, although further exploration for cancer-specific and localized
targeting is warranted in order to protect noncancerous cells from glucose deprivation.
Preclinical models have demonstrated that disrupting lactate transport with diclofenac-
mediated MCT-inhibition, neutralizing intratumoral pH with oral bicarbonate treatment,
or counteracting intratumoral hypoxia with metformin can synergize with ICT [68,76]
In conclusion, disrupting UC metabolism may be a new approach to boost ICT for
BC patients. Novel druggable targets are being explored in preclinical models, but the
repurposing of existing drugs to disrupt the glucose metabolism (metformin) or lactate
transport (diclofenac) and boost ICT should be investigated as well.
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